Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance.

ABSTRACT: New tuberculosis (TB) drugs with little existing antimicrobial resistance enable a pan-TB treatment regimen, intended for universal use without prior drug-susceptibility testing. However, widespread use of such a regimen could contribute to an increasing prevalence of antimicrobial resistance, potentially rendering the pan-TB regimen ineffective or driving clinically problematic patterns of resistance. We developed a model of multiple sequential TB patient cohorts to compare treatment outcomes between continued use of current standards of care (guided by rifampin-susceptibility testing) and a hypothetical pan-TB approach. A pan-TB regimen that met current target profiles was likely to initially outperform the standard of care; however, a rising prevalence of transmitted resistance to compo

SUBMITTER: McQuaid CF 

PROVIDER: S-EPMC11286077 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature